SOURCE: Vestiq Pharmaceuticals

Vestiq Pharmaceuticals

June 05, 2013 08:00 ET

Vestiq Pharmaceuticals Offers MagBID ER Magnesium Dietary Supplement for Patients Who Have Lost Magnesium Because of Illness or Treatment With Certain Medicines

MORRISVILLE, NC--(Marketwired - Jun 5, 2013) -  Vestiq Pharmaceuticals, Inc. today announced that it will add MagBID ER (magnesium L-lactate dehydrate) tablets to its growing list of supportive care products. Rights to the product were purchased from Niche Pharmaceuticals. The products will be marketed and distributed by Vestiq's supportive care company, Praelia Pharmaceuticals.

MagBID ER is used as a dietary supplement for individuals who are deficient in magnesium. Although a balanced diet usually supplies all the magnesium a person needs, magnesium supplements may be needed by patients who have lost magnesium because of illness or treatment with certain medicines.1

According to the U.S. Food and Drug Administration, low serum magnesium levels can result in serious adverse events including muscle spasm (tetany), irregular heartbeat (arrhythmias), and convulsions (seizures); however, patients do not always have these symptoms.2

Magnesium Deficiency and Cancer Drugs
Muhammad Wasif Saif, MD, MBBS, Associate Professor Medical Oncology, Yale University School of Medicine, writes in the Journal of Supportive Oncology that "Hypomagnesemia is a relatively common side effect of certain anticancer drugs, especially cisplatin, cyclosporine, and anti-EGFR agents, including cetuximab and panitumumab. Risk factors include a patient's age and baseline magnesium level. The impact of hypomagnesemia is underestimated largely because clinicians fail to measure magnesium levels. Hypomagnesemia is associated with significant morbidity. Therefore we recommend a proactive approach in managing hypomagnesemia in cancer patients receiving such agents."3

Higher Magnesium Absorption
More than 40% of MagBID ER is found to be absorbed in the blood stream, which is more than double the absorption rate of other leading magnesium supplements, according to independent studies.4

Each MagBID ER caplet contains 84 mg of elemental magnesium L-lactate dihydrate. Four 84 mg Mag-Tab SR caplets daily contain 336 mg of magnesium and will meet the USRDA range for the average adult female and male (300-350 mg daily).

"Because magnesium products' solubility, absorption, and bioavailability affect patient response, it would likely require patients to take significantly more tablets of other magnesium products to provide the same amount of bioavailable magnesium as with each tablet of MagBID ER," said Steve Lutz, President, Praelia Pharmaceuticals.

For more information and to purchase MagBID ER, visit www.MagBIDER.com.

About Vestiq Holdings
 
Vestiq is a Specialty Pharmaceutical Company focused on innovative therapeutic remedies within the supportive care markets. Vestiq is committed to becoming the market leader in providing pharmaceutical products and technologies to the supportive care market. The company's portfolio is supported by strong intellectual property, a pipeline of other supportive care prescription products, and a strong commercialization team of industry experts.

1 These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure or prevent any disease.

2 http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm

3 Saif, MW: Journal of Supportive Oncology, 6:5, May/June 2008, Management of Hypomagnesemia in Cancer Patients Receiving Chemotherapy

4 Klein, M: CVR&R; 1994; (15) 10: 9-56; Gullestad L: Magnes Trace Elem 1991-92; 10 (1): 11-16; White, J Massey L: Clin Ther 1992; 1992 14 (5): 678-687; Linberg JS: J Am Coll Nutr 1990; 9 (1) 48-55; Knochel TL: Harrison's Principles of Internal Medicine 1991; 1935-1938; Fine KD: J Clin Invest 1991; 2:396-402.

Contact Information